Mínimo flujo de oxígeno necesario para soporte vital durante la simulación de reanimación post parada cardiorrespiratoria / Minimum oxygen flow needed for vital support during simulated post-cardiorespiratory arrest resuscitation

De acuerdo con las guías de la AHA y la ERC, la FiO2 a administrarse debería ser aquella con la que se obtuviera una SatO2 ≥ 94%. El objetivo de este estudio es determinar el mínimo flujo de oxígeno y tiempo necesarios para alcanzar una FiO2 de 0,32 y de 0,80 durante el manejo posparada cardiaca. Se emplearon diferentes reanimadores, que fueron conectados a un pulmón artificial: Mark IV, SPUR II, Revivator Res-Q, O-TWO. Los flujos de oxígeno probados fueron 2, 5, 10 y 15 lpm. Los test estadísticos aplicados fueron Bonferroni y U de Mann-Whitney. Se obtuvo una FiO2 ≥ 0,32 con cualquiera de los flujos de oxígeno y reanimadores. Tras un mínimo de 75 s ventilando con 2 o 5 lpm, solo se consiguió una FiO2 de 0,80 con Mark IV. Se hallaron diferencias clínica y estadísticamente significativas (p < 0,05): con 15 lpm se necesitaron 35 s para alcanzar una FiO2 ≥ 0,80 con Mark IV (85,6 [0,3]) y Revivator (84,3 [1,5]) comparado con los 50 s que precisó SPUR II (87,1 [6,4]); con 2 lpm, todos los resucitadores alcanzaron una FiO2 ≥ 0,32 en 30 s(Mark IV (34,8 [1,3]), Revivator (35,7 [1,5]) y SPUR II (34,4 [2,1]), excepto O-TWO, que necesitó 35 s (36,3 [4,3]). Para alcanzar una FiO2 de 0,32 se podría emplear cualquiera de los resucitadores usando 2 lpm, aunque quizá el menos recomendable sería O-TWO. Si el objetivo fuera una FiO2 de 0,80, debería bastar con 10 lpm, usando preferiblemente Mark IV o Revivator Res-Q. En conclusión, atendiendo a los resultados de nuestro estudio, ante cualquier situación potencial, sería preferible emplear Revivator Res-Q o Mark IV que O-TWO o SPUR II (AU)

According to the ERC and the AHA guidelines, FiO2 should be titrated to achieve an O2Sat ≥ 94%. The aim of this study was to determine the minimum oxygen flow and time needed to reach an FiO2 of 0.32 and 0.80 during post-cardiac arrest care. An experimental analysis was performed that consisted of a simulated post-cardiac arrest situation. Different resuscitators were tested and connected to an artificial lung: Mark IV, SPUR II, Revivator Res-Q, O-TWO. The oxygen flow levels tested were 2, 5, 10 and 15 lpm. Bonferroni and Mann-Whitney U tests were used. An FiO2 of 0.32 or more was obtained using any of the oxygen flow and resuscitators. Only the Mark IV achieved an FiO2 of 0.80 after a minimum of 75 s ventilating with 2 or 5 lpm. Clinical and statistical differences (P < .05) were found: at 15 lpm it took 35 s to reach an FiO2 of 0.80 or more for Mark IV (85.6 [0.3]) and Revivator (84.3 [1.5]) compared to 50 s for SPUR II (87.1 [6.4]); at 2 lpm, all of the devices reached an FiO2 of ≥ 0.32 at 30 s(Mark IV (34.8 [1.3]), Revivator (35.7 [1.5]) and SPUR II (34.4 [2.1]), except for O-TWO, which took 35 s (36.3 [4.3]). Patients could be ventilated with any of the resuscitators using 2 lpm to obtain an FiO2 of 0.32, although possibly O-TWO would be the last option during the first 60 s. In order to reach an FiO2 of 0.80, ventilating with 10 lpm should be sufficient, and preferably using Mark IV or Revivator Res-Q. In conclusion, on observing the results of our study, in any possible scenario, it would be advisable to use Revivator Res-Q or Mark IV rather than O-TWO or SPUR II (AU)

Minimum oxygen flow needed for vital support during simulated post-cardiorespiratory arrest resuscitation.

According to the ERC and the AHA guidelines, FiO2 should be titrated to achieve an O2Sat ≥ 94%. The aim of this study was to determine the minimum oxygen flow and time needed to reach an FiO2 of 0.32 and 0.80 during post-cardiac arrest care. An experimental analysis was performed that consisted of a simulated post-cardiac arrest situation. Different resuscitators were tested and connected to an artificial lung: Mark IV, SPUR II, Revivator Res-Q, O-TWO. The oxygen flow levels tested were 2, 5, 10 and 15 lpm. Bonferroni and Mann-Whitney U tests were used. An FiO2 of 0.32 or more was obtained using any of the oxygen flow and resuscitators. Only the Mark IV achieved an FiO2 of 0.80 after a minimum of 75s ventilating with 2 or 5 lpm. Clinical and statistical differences (P<.05) were found: at 15 lpm it took 35s to reach an FiO2 of 0.80 or more for Mark IV (85.6 [0.3]) and Revivator (84.3 [1.5]) compared to 50s for SPUR II (87.1 [6.4]); at 2 lpm, all of the devices reached an FiO2 of ≥ 0.32 at 30s(Mark IV (34.8 [1.3]), Revivator (35.7 [1.5]) and SPUR II (34.4 [2.1]), except for O-TWO, which took 35s (36.3 [4.3]). Patients could be ventilated with any of the resuscitators using 2 lpm to obtain an FiO2 of 0.32, although possibly O-TWO would be the last option during the first 60s. In order to reach an FiO2 of 0.80, ventilating with 10 lpm should be sufficient, and preferably using Mark IV or Revivator Res-Q. In conclusion, on observing the results of our study, in any possible scenario, it would be advisable to use Revivator Res-Q or Mark IV rather than O-TWO or SPUR II.

Trends of asthma mortality in Galicia from 1993 to 2007.

INTRODUCTION: In the past few years, deaths due to asthma appear to decrease at least in Western countries; but there are significant variations between populations. The aim of this study is to describe the trends in deaths due to asthma between 1993 and 2007 in our community and to analyze any factors associated with this. METHODS: All cases, which had asthma as a cause of death, were included in the study. The mortality data were obtained from the official death certificate from the Deaths Register. Mortality relative risk, based on the calendar year, sociodemographic variables (age and gender), seasons, and days of the week, were estimated using a Poisson generalized linear model with a log-link. RESULTS: In the 15 years of the study period, a total of 1180 people had died due to asthma, mainly in winter (34.5%), women (64.5%), and advanced age (65 years or above; 84.6%). A tendency of decreased mortality in all age groups was observed during the period of the study, which was significant in both the sexes in the 35- to 64-year-old age group, and in males above 65 years. CONCLUSION: Death due to asthma is changing favorably in our community, with a tendency to decrease in the past few years. Advanced age, being female, and the winter period are associated with a higher mortality rate due to asthma.